Switch theme
Sign up to access all valuation multiples
M1 Kliniken AG is a healthcare company operating in the market for aesthetic medical treatment and plastic surgery. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical, and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. The majority of its revenue is derived from the Trade segment.
2007
219
LTM Revenue $412M
LTM EBITDA $38.8M
$312M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
M1 Kliniken has a last 12-month revenue (LTM) of $412M and a last 12-month EBITDA of $38.8M.
In the most recent fiscal year, M1 Kliniken achieved revenue of $399M and an EBITDA of $39.4M.
M1 Kliniken expects next 12-month revenue of XXX and NTM EBITDA of XXX
See M1 Kliniken valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $412M | XXX | $399M | XXX | XXX | XXX |
| Gross Profit | $76.9M | XXX | $74.9M | XXX | XXX | XXX |
| Gross Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA | $38.8M | XXX | $39.4M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $32.5M | XXX | $30.7M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $20.2M | XXX | $18.9M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, M1 Kliniken's stock price is EUR 15 (or $17).
M1 Kliniken has current market cap of EUR 278M (or $327M), and EV of EUR 265M (or $312M).
See M1 Kliniken trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $312M | $327M | XXX | XXX | XXX | XXX | $1.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, M1 Kliniken has market cap of $327M and EV of $312M.
M1 Kliniken's trades at 0.8x EV/Revenue multiple, and 7.9x EV/EBITDA.
Equity research analysts estimate M1 Kliniken's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
M1 Kliniken has a P/E ratio of 16.2x.
See valuation multiples for M1 Kliniken and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $327M | XXX | $327M | XXX | XXX | XXX |
| EV (current) | $312M | XXX | $312M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | 10.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.2x | XXX | 17.3x | XXX | XXX | XXX |
| EV/FCF | 12.0x | XXX | 9.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialM1 Kliniken's last 12 month revenue growth is 7%
M1 Kliniken's revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $0.2M for the same period.
M1 Kliniken's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
M1 Kliniken's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for M1 Kliniken and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
M1 Kliniken acquired XXX companies to date.
Last acquisition by M1 Kliniken was XXXXXXXX, XXXXX XXXXX XXXXXX . M1 Kliniken acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was M1 Kliniken founded? | M1 Kliniken was founded in 2007. |
| Where is M1 Kliniken headquartered? | M1 Kliniken is headquartered in Germany. |
| How many employees does M1 Kliniken have? | As of today, M1 Kliniken has 219 employees. |
| Is M1 Kliniken publicy listed? | Yes, M1 Kliniken is a public company listed on ETR. |
| What is the stock symbol of M1 Kliniken? | M1 Kliniken trades under M12 ticker. |
| When did M1 Kliniken go public? | M1 Kliniken went public in 2015. |
| Who are competitors of M1 Kliniken? | Similar companies to M1 Kliniken include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of M1 Kliniken? | M1 Kliniken's current market cap is $327M |
| What is the current revenue of M1 Kliniken? | M1 Kliniken's last 12 months revenue is $412M. |
| What is the current revenue growth of M1 Kliniken? | M1 Kliniken revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of M1 Kliniken? | Current revenue multiple of M1 Kliniken is 0.8x. |
| Is M1 Kliniken profitable? | Yes, M1 Kliniken is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of M1 Kliniken? | M1 Kliniken's last 12 months EBITDA is $38.8M. |
| What is M1 Kliniken's EBITDA margin? | M1 Kliniken's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of M1 Kliniken? | Current EBITDA multiple of M1 Kliniken is 8.0x. |
| What is the current FCF of M1 Kliniken? | M1 Kliniken's last 12 months FCF is $25.9M. |
| What is M1 Kliniken's FCF margin? | M1 Kliniken's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of M1 Kliniken? | Current FCF multiple of M1 Kliniken is 12.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
